Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Wet Macular Degeneration”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT03677934
What this trial is testing

A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration
Hoffmann-La Roche 415
Post-approval studies (Phase 4)Study completedNCT04774926
What this trial is testing

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 122
Post-approval studies (Phase 4)UnknownNCT00813891
What this trial is testing

Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration

Who this might be right for
Macular DegenerationVisual Acuity
McGill University Health Centre/Research Institute of the McGill University Health Centre 180
Early research (Phase 1)Study completedNCT03748784
What this trial is testing

ADVM-022 Intravitreal Gene Therapy for Wet AMD

Who this might be right for
Wet Age-related Macular DegenerationNeovascular Age-related Macular Degeneration
Adverum Biotechnologies, Inc. 30
Early research (Phase 1)Ended earlyNCT00102115
What this trial is testing

Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease

Who this might be right for
Macular DegenerationChoroidal Neovascularization
Light Sciences LLC 27
Large-scale testing (Phase 3)Study completedNCT04857177
What this trial is testing

Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration

Who this might be right for
Neovascular(Wet) Age Related Macular Degeneration
Chong Kun Dang Pharmaceutical 312
Testing effectiveness (Phase 2)Study completedNCT01134055
What this trial is testing

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

Who this might be right for
Macular Degeneration
GlaxoSmithKline 510
Large-scale testing (Phase 3)Not Yet RecruitingNCT07520318
What this trial is testing

This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.

Who this might be right for
Adults With Neovascular Age-related Macular Degeneration
Shenzhen Oculgen Biomedical Technology Co., Ltd. 255
Large-scale testing (Phase 3)UnknownNCT04572698
What this trial is testing

Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）

Who this might be right for
Age Related Macular Degeneration
Luye Pharma Group Ltd. 416
Not applicableStudy completedNCT04847895
What this trial is testing

Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications

Who this might be right for
Neovascular (Wet) Age-related Macular Degeneration
Novartis Pharmaceuticals 5,500
Early research (Phase 1)Study completedNCT03585556
What this trial is testing

AAVCAGsCD59 for the Treatment of Wet AMD

Who this might be right for
Wet Age-related Macular Degeneration
Janssen Research & Development, LLC 25
Not applicableNot Yet RecruitingNCT06759597
What this trial is testing

The Effect of Phacoemulsification on the Macular Changes in Patients with Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular (wet) Age-Related Macular Degeneration
Assiut University 50
Not applicableStudy completedNCT05082415
What this trial is testing

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals 9,456
Not applicableStudy completedNCT05146687
What this trial is testing

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals 369,600
Testing effectiveness (Phase 2)Looking for participantsNCT04504123
What this trial is testing

MMP-9 Inhibition for Recalcitrant Wet AMD

Who this might be right for
Exudative Macular DegenerationWet Age-related Macular Degeneration
University of Iowa 50
Post-approval studies (Phase 4)Study completedNCT01972789
What this trial is testing

Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)

Who this might be right for
Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
Novartis Pharmaceuticals 349
Not applicableEnded earlyNCT03699618
What this trial is testing

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

Who this might be right for
Submacular HemorrhageWet Macular DegenerationNeovascular Age-related Macular Degeneration
Johns Hopkins University 1
Post-approval studies (Phase 4)Study completedNCT02257632
What this trial is testing

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Who this might be right for
Wet Age-Related Macular Degeneration
Novartis Pharmaceuticals 41
Testing effectiveness (Phase 2)Enrolling By InvitationNCT03999801
What this trial is testing

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

Who this might be right for
Neovascular Age-related Macular DegenerationWet Macular Degeneration
AbbVie 865
Large-scale testing (Phase 3)Ended earlyNCT04049266
What this trial is testing

Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Who this might be right for
Wet Macular Degeneration
Kodiak Sciences Inc 559
Next Page